NASDAQ | VICL: 1.27  +0.00
investors
Investors

News Releases

DateSubject
December 17, 2013 Vical Announces Initiation of Phase 1/2 Trial of a Therapeutic HSV-2 Vaccine for Genital Herpes
December 10, 2013 Astellas and Vical Announce Initiation of Phase 2 Trial of ASP0113, a Cytomegalovirus Vaccine, in Solid Organ Transplant Recipients
November 18, 2013 Presentation of Vical's Allovectin(R) Phase 3 Results Scheduled at Society for Melanoma Research Meeting
November 6, 2013 Vical to Present at 2013 Credit Suisse Healthcare Conference
October 31, 2013 Vical Reports Third Quarter 2013 Financial Results and Progress in Key Development Programs
October 24, 2013 Vical Reviews Herpes Simplex Vaccine Progress at 2nd International Conference and Exhibition on Cell & Gene Therapy
October 24, 2013 Vical Announces News Release and Conference Call Schedule for Third Quarter 2013 Financial Results
October 3, 2013 Vical Publication Highlights Milestone in Vaccine Development
September 6, 2013 Vical to Present at September Investor Conferences
August 22, 2013 Vical Announces Restructuring and Staff Reduction
August 12, 2013 Vical Phase 3 Trial of Allovectin(R) Fails to Meet Efficacy Endpoints
August 11, 2013 Vical Announces Conference Call and Webcast to Discuss Allovectin(R) Phase 3 Results
August 1, 2013 Vical Reports Second Quarter 2013 Financial Results, Projects Phase 3 Data Release in August and Establishes Quiet Period
July 25, 2013 Vical Announces News Release and Conference Call Schedule for Second Quarter 2013 Financial Results
July 3, 2013 Vical to Present at JMP Securities Healthcare Conference
June 25, 2013 Vical and Astellas Announce Initiation of Phase 3 Trial of ASP0113 Cytomegalovirus Vaccine
June 12, 2013 Vical to Present at Wells Fargo Securities Healthcare Conference
May 23, 2013 Vical Appoints Richard M. Beleson and Stephen A. Sherwin, M.D., to Board of Directors
May 9, 2013 Vical Reports First Quarter 2013 Financial Results and Progress in Key Development Programs
May 7, 2013 Vical to Present at May Investor Conferences
May 6, 2013 Vaxfectin(R) Enhances Preclinical Immune Responses to Baxter's Cell Culture-Derived Influenza Vaccines
May 2, 2013 Vical Announces News Release and Conference Call Schedule for First Quarter 2013 Financial Results
April 22, 2013 Vical CEO to Participate in Cancer Immunotherapy Panel at BIO International Convention
February 27, 2013 Vical to Present at March Investor Conferences
February 6, 2013 Vical Reports 2012 Financial Results and Progress in Key Development Programs
February 5, 2013 Vical to Present at February Investor Conferences
February 4, 2013 Vical Announces Publication of Herpes Simplex Vaccine Guinea Pig Study Data
January 30, 2013 Vical Announces News Release and Conference Call Schedule for 2012 Financial Results
January 3, 2013 Vical to Present at 31st Annual J.P. Morgan Healthcare Conference
January 2, 2013 Vical Named to NASDAQ Global Select Market

P. 858 646 1100 10390 Pacific Center Court, San Diego, California 92121
Designed by Mentus
This link to a non-Vical website is provided as a resource. Vical assumes no responsibility for content not provided by Vical, or for practices or standards of any non-Vical websites.